New Urine Test Could Predict Response to Bladder Cancer Treatment

Researchers have developed a urine test that can screen for tumor DNA and detect whether a patient has residual bladder cancer after they have undergone surgery to remove the tumor. This test may also detect whether immunotherapy treatment administered after surgery has been effective or residual bladder cancer remains. As more forms of immunotherapy are developed by companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are indicated for bladder cancer, such a non-invasive diagnostic tool could become crucial in monitoring treatment response.

Bladder cancer is one of the most common cancers, with high recurrence rates even after surgical removal of tumors. Currently, monitoring for residual disease often involves invasive cystoscopy, which can be uncomfortable and costly. The new urine test offers a non-invasive alternative that could improve patient compliance and enable earlier detection of recurrence. By identifying tumor DNA shed into urine, the test provides a molecular snapshot of the cancer status.

The implications for immunotherapy are significant. Immunotherapy drugs, such as checkpoint inhibitors, have revolutionized treatment for advanced bladder cancer, but not all patients respond. The ability to quickly determine whether immunotherapy is working could spare patients from ineffective treatments and their side effects. This test could also help in clinical trials by providing a biomarker to assess drug efficacy.

BioMedWire (BMW), a communications platform focused on the biotechnology and life sciences sectors, covered this development. BMW is part of the Dynamic Brand Portfolio @IBN, which provides access to a network of wire solutions via InvestorWire to reach target markets. The platform also offers article and editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution. For more information, visit https://www.BioMedWire.com.

This urine test represents a step forward in personalized medicine for bladder cancer, potentially reducing the need for invasive procedures and enabling more timely treatment adjustments. As research progresses, validation in larger studies will be necessary to bring this test into routine clinical use.